Today's sweep found no new drug approvals, safety communications or guideline changes relevant to diabetes care. That is reported as it stands, because a quiet day is worth knowing about rather than filling.
The most recent relevant decisions remain a batch of supplemental approvals issued on 11 August, all for fixed-dose metformin combinations already on the market: sitagliptin with metformin, as Zituvimet and Zituvimet XR from Zydus Lifesciences, linagliptin with metformin as Jentadueto and Jentadueto XR, empagliflozin with metformin as Synjardy, and the empagliflozin, linagliptin and metformin triple as Trijardy XR, the last four from Boehringer Ingelheim. Supplemental approvals of this kind cover manufacturing, labelling or formulation changes. None introduces a new molecule or a new indication, and none is new today.
There is nothing to act on. The standing change that still matters is the 2026 dyslipidaemia guideline covered earlier this week, which lowered LDL cholesterol targets and widened statin eligibility. If you have not yet reviewed your patients against the new targets, that remains the outstanding piece of work, and it is not anything published today.
- No new approvals, withdrawals or safety communications in diabetes today.
- The 11 August actions were supplemental approvals of existing metformin combinations, with no new molecule or indication.
- Fixed-dose combinations matter mainly for adherence and cost; check what your patient can actually obtain locally.
- Indian availability and pricing of these combinations differ from the US label, so do not read an FDA supplement as a change in Indian practice.
- Still outstanding from this week: reviewing patients against the 2026 lipid targets.
The statistics, in plain English
There are no statistics to interpret here, which is the point. The sweep covers FDA approvals and safety communications and the major guideline bodies, and it returned nothing dated today. A zero is a result rather than a gap: it means there is no new signal to act on, not that nothing was looked for.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free